...Adrian Duek; Luba Trakhtenbrot; Abraham Avigdor; Arnon Nagler; Merav Leiba Introduction: Multiple myeloma (MM) is uncommon in persons younger than 50 years of age. The presenting features in this age group are unclear. Methods: We analyzed a cohort of patients <50 years of age with MM treated...

...Sophie C. Ragbourne; Negar Maghsoodi; Matthew Streetly; Martin A. Crook Multiple myeloma (MM) is a haematological malignancy arising from monoclonal proliferation of plasma cells in the bone marrow, resulting in the presence of paraproteins or M-protein in serum. The involvement of paraproteins...

...Eleonora Ghisoni; Laura Marandino; Pasquale Lombardi; Alessandro Bonzano; Paolo Becco; Massimo Aglietta; Marco Fizzotti; Francesca Gay; Delia Rota Scalabrini Cardiovascular adverse events (CVAEs) are of considerable importance in patients with multiple myeloma (MM), given the significant prevalence...

...Raphael E. Steiner; Robert Z. Orlowski; Hans C. Lee Background: Acute pancreatitis is an uncommon complication of anti-myeloma agents. Ixazomib is a first-in-class oral proteasome inhibitor to receive regulatory approval for the treatment of multiple myeloma. This case report describes the first...

...Won Jin Chang; Eun-Suk Kang; Seung-Tae Lee; Sun-Hee Kim; Dae Won Kim; Seok Jin Kim; Kihyun Kim This study explored the effect of thalidomide and cyclophosphamide on stem cell collection, in addition to assessing their efficacy as induction therapy for myeloma patients destined for autologous stem...

...A.H. Goldstone; J.K. Wood; M.K. Cook The occurrence of multiple myeloma in mother and daughter is described. To the best of our knowledge, this has not been previously reported with both famismaly members available for detailed study. 4 3 2009 © 1973 S. Karger AG, Basel 1973...

...J.C. Cawley; A.H. Goldstone; J. Arno; J.H.K. Rees; A. Grant This report describes the clinical and pathological features of a case of nodular sclerosing Hodgkin’s disease treated with a variety of chemotherapeutic agents who developed fulminating IgG myeloma approximately 26 months after...

...Anna Maria Ferraris; Enrico Haupt; Massimo Ratti A case of nonproductor myeloma is reported. The diagnosis was supported by the radiological findings, the heavy marrow infiltration of malignant plasma cells, the absence of a monoclonal component in the serum or urine and the failure to demonstrate...

...Peter V. Sacks; Mehdi Tavassoli; Ted Eastlund A patient in whom lymphocyte-depleted Hodgkin’s disease and multiple myeloma were diagnosed simultaneously is reported. There was no prior history of irradiation or chemotherapy, the significance of which is discussed in relation to previously...

..., R onald A. Preston, Matthew D. Carson, Atsushi Komiyama and Samuel S. Spicer Hematology Division, Department of Medicine, and DepartmeVntetoefraPnasthAodlomgiyn,isMtraedtiiocnalHUonspivietarls,itCyhoafrlSeostuotnh, CS.aCro.lina, and Key Words. Cytoplasmic fibrils Myeloma Plasma cell leukemia...

...Dina Meytes; Uri Seligsohn; Bracha Ramot A patient with multiple myeloma treated by melphalan terminated in erythroleukemia. The evolution of the leukemia was preceded by a protracted preleukemic phase, as evidenced by progressive pancytopenia. The possible implications of an early diagnosis...

...J. Jansen; P. Blok Most plasmacytomas of lymph nodes are secondary metastases from myeloma or from primary plasmacytoma of the upper air passages. Primary plasmacytomas of lymph nodes are very rare. A case of primary plasmacytoma of mediastinal, cervical and para-aortic lymph nodes is reported...

...L. Parapia; C.R. Abbott; G.M. Masters; B.E. Roberts A patient in whom acute myelomonocytic leukaemia and multiple myeloma were found to exist simultaneously at presentation is described. A review of similar cases in the literature is presented. 30 11 1981 21 12 1981 26 2 2009...

...David A. Cooper; Andrew C. Miller; Ronald Penny Tumour cell mass (TCM) in patients with multiple myeloma has been measured by synthetic rate studies of bone-marrow tumor cells in culture. From the measurements of Salmon and co-workers, a simple clinical staging system in which TCM is calculated...

... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. IgDλ paraprotein J-chain Leukaemia Myeloma Plasma cell Primary plasma cell leukaemia Acta haemat. 70: 122-129(1983) © 1983 S. Karger AG, Basel 0001-5792783/0702-0122...

..., suggesting that resistance to this dose of melphalan occurs early even in responding patients 28 10 1986 18 04 1987 25 2 2009 Drug resistance Melphalan Myeloma Acta haemat. 78: 233-238(1987) © 1987 S. Karger AG. Basel 0001-5792/87/0784-0233 $ 2.75/0 Short Course Intermediate Dose...

...Kimberley McGinnes; Ronald Penny The aim of this study was to determine the effects of interferon on in vitro immunoglobulin synthesis by the plasma cells of patients with multiple myeloma. Bone marrow cultures were set up in the presence of media alone or α-interferon. Supernatants were harvested...

...Hiroyuki Hata; Hiromitsu Matsuzaki; Kiyoshi Takatsuki The effects of tumor necrosis factor α (TNF-α) and interleukin-6 (IL-6) on the cell growth of the myeloma cell line KHM-1A were studied. TNF-α strongly induced KHM-1A proliferation, while IL-6 weakly enhanced growth only at low cell densities...

...Hans Bäck; Ragnar Lindblad; Stig Rödjer; Jan Westin Eight patients with progressive multiple myeloma were given an intermediate intravenous dose of melphalan (30 mg/m 2 ). A response lasting 2–18 months was observed in 7 patients. The bone marrow toxicity was well acceptable and most courses could...

...Yi-Hsiang Chen; Xin-Xiang Feng; Lawrence Schilder The effect of in vitro exposure to vincristine, Adriamycin®, and glucocorticoids was studied in 4 human myeloma cell lines. The drug concentrations tested approximated the steady-state plasma level achievable clinically. Marked growth inhibition...